Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2008

Open Access 01-12-2008 | Research

The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group

Authors: Prakash Chinnaiyan, Meihua Wang, Amyn M Rojiani, Philip J Tofilon, Arnab Chakravarti, K Kian Ang, Hua-Zhong Zhang, Elizabeth Hammond, Walter Curran Jr, Minesh P Mehta

Published in: Radiation Oncology | Issue 1/2008

Login to get access

Abstract

Background

Nestin is an intermediate filament protein that has been implicated in early stages of neuronal lineage commitment. Based on the heterogeneous expression of nestin in GBM and its potential to serve as a marker for a dedifferentiated, and perhaps more aggressive phenotype, the Radiation Therapy Oncology Group (RTOG) sought to determine the prognostic value of nestin expression in newly diagnosed GBM patients treated on prior prospective RTOG clinical trials.

Methods

Tissue microarrays were prepared from 156 patients enrolled in these trials. These specimens were stained using a mouse monoclonal antibody specific for nestin and expression was measured by computerized quantitative image analysis using the Ariol SL-50 system. The parameters measured included both staining intensity and the relative area of expression within a specimen. This resulted into 3 categories: low, intermediate, and high nestin expression, which was then correlated with clinical outcome.

Results

A total of 153 of the 156 samples were evaluable for this study. There were no statistically significant differences between pretreatment patient characteristics and nestin expression. There was no statistically significant difference in either overall survival or progression-free survival (PFS) demonstrated, although a trend in decreased PFS was observed with high nestin expression (p = 0.06).

Conclusion

Although the correlation of nestin expression and histologic grade in glioma is of considerable interest, the presented data does not support its prognostic value in newly diagnosed GBM. Further studies evaluating nestin expression may be more informative when studied in lower grade glioma, in the context of markers more specific to tumor stem cells, and using more recent specimens from patients treated with temozolomide in conjunction with radiation.
Appendix
Available only for authorised users
Literature
1.
Hockfield S, McKay RD: Identification of major cell classes in the developing mammalian nervous system. J Neurosci 1985,5(12):3310-3328.PubMed
2.
Lendahl U, Zimmerman LB, McKay RD: CNS stem cells express a new class of intermediate filament protein. Cell 1990,60(4):585-595. 10.1016/0092-8674(90)90662-XCrossRefPubMed
3.
Holland EC: Progenitor cells and glioma formation. Curr Opin Neurol 2001,14(6):683-688. 10.1097/00019052-200112000-00002CrossRefPubMed
4.
Wiese C, Rolletschek A, Kania G, Blyszczuk P, Tarasov KV, Tarasova Y, Wersto RP, Boheler KR, Wobus AM: Nestin expression–a property of multi-lineage progenitor cells? Cell Mol Life Sci 2004,61(19–20):2510-2522. 10.1007/s00018-004-4144-6CrossRefPubMed
5.
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature 2004,432(7015):396-401. 10.1038/nature03128CrossRefPubMed
6.
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006,444(7120):756-760. 10.1038/nature05236CrossRefPubMed
7.
Chou YH, Khuon S, Herrmann H, Goldman RD: Nestin promotes the phosphorylation-dependent disassembly of vimentin intermediate filaments during mitosis. Mol Biol Cell 2003,14(4):1468-1478. 10.1091/mbc.E02-08-0545PubMedCentralCrossRefPubMed
8.
Sahlgren CM, Mikhailov A, Hellman J, Chou YH, Lendahl U, Goldman RD, Eriksson JE: Mitotic reorganization of the intermediate filament protein nestin involves phosphorylation by cdc2 kinase. J Biol Chem 2001,276(19):16456-16463. 10.1074/jbc.M009669200CrossRefPubMed
9.
Sahlgren CM, Pallari HM, He T, Chou YH, Goldman RD, Eriksson JE: A nestin scaffold links Cdk5/p35 signaling to oxidant-induced cell death. Embo J 2006,25(20):4808-4819. 10.1038/sj.emboj.7601366PubMedCentralCrossRefPubMed
10.
Thomas SK, Messam CA, Spengler BA, Biedler JL, Ross RA: Nestin is a potential mediator of malignancy in human neuroblastoma cells. J Biol Chem 2004,279(27):27994-27999. 10.1074/jbc.M312663200CrossRefPubMed
11.
Dahlstrand J, Collins VP, Lendahl U: Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 1992,52(19):5334-5341.PubMed
12.
Tohyama T, Lee VM, Rorke LB, Marvin M, McKay RD, Trojanowski JQ: Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Invest 1992,66(3):303-313.PubMed
13.
Ma YH, Mentlein R, Knerlich F, Kruse ML, Mehdorn HM, Held-Feindt J: Expression of stem cell markers in human astrocytomas of different WHO grades. J Neurooncol 2008,86(1):31-45. 10.1007/s11060-007-9439-7CrossRefPubMed
14.
Maderna E, Salmaggi A, Calatozzolo C, Limido L, Pollo B: Nestin, PDGFRbeta, CXCL12 and VEGF in Glioma Patients: Different Profiles of (Pro-Angiogenic) Molecule Expression Are Related with Tumor Grade and May Provide Prognostic Information. Cancer Biol Ther 2007.,6(7):
15.
Mao Y, Zhou L, Zhu W, Wang X, Yang G, Xie L, Mao X, Jin K: Proliferative status of tumor stem cells may be correlated with malignancy grade of human astrocytomas. Front Biosci 2007, 12: 2252-2259. 10.2741/2227CrossRefPubMed
16.
Schiffer D, Manazza A, Tamagno I: Nestin expression in neuroepithelial tumors. Neurosci Lett 2006,400(1–2):80-85. 10.1016/j.neulet.2006.02.034CrossRefPubMed
17.
Strojnik T, Rosland GV, Sakariassen PO, Kavalar R, Lah T: Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol 2007,68(2):133-143. discussion 143-134. 10.1016/j.surneu.2006.10.050CrossRefPubMed
18.
Chakravarti A, Seiferheld W, Tu X, Wang H, Zhang HZ, Ang KK, Hammond E, Curran W Jr, Mehta M: Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005,62(2):318-327.CrossRefPubMed
19.
Yang X, Wu Q, Yu X, Xu C, Ma B, Zhang X, Li S, Lahn B, Xiang AP: Nestin expression in different tumors and its relevance to malignant grade. J Clin Pathol 2008,61(4):467-473. 10.1136/jcp.2007.047605CrossRefPubMed
20.
Sugawara K, Kurihara H, Negishi M, Saito N, Nakazato Y, Sasaki T, Takeuchi T: Nestin as a marker for proliferative endothelium in gliomas. Lab Invest 2002,82(3):345-351.CrossRefPubMed
21.
Brychtova S, Fiuraskova M, Hlobilkova A, Brychta T, Hirnak J: Nestin expression in cutaneous melanomas and melanocytic nevi. J Cutan Pathol 2007,34(5):370-375. 10.1111/j.1600-0560.2006.00627.xCrossRefPubMed
22.
Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR: Increased expression of stem cell markers in malignant melanoma. Mod Pathol 2007,20(1):102-107. 10.1038/modpathol.3800720CrossRefPubMed
23.
Li H, Cherukuri P, Li N, Cowling V, Spinella M, Cole M, Godwin AK, Wells W, DiRenzo J: Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res 2007,67(2):501-510. 10.1158/0008-5472.CAN-05-4571CrossRefPubMed
24.
Ehrmann J, Kolar Z, Mokry J: Nestin as a diagnostic and prognostic marker: immunohistochemical analysis of its expression in different tumours. J Clin Pathol 2005,58(2):222-223. 10.1136/jcp.2004.021238PubMedCentralCrossRefPubMed
25.
Mirimanoff R, Mason W, Bent M, Kortmann R, Taphoorn M, Brandes A, Villa S, Cairncross G, Gorlia T, Stupp R: Is Long-Term Survival in Glioblastoma Possible? Updated Results of the EORTC/NCIC Phase III randomized Trial on Radiotherapy (RT) and Concomitant and Adjuvant Temozolomide (TMZ) vesus RT Alone. Int J Radiat Oncol Biol Phys 2007,69(3):S1.
26.
Stupp R, Mason WP, Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005,352(10):987-996. 10.1056/NEJMoa043330CrossRefPubMed
Metadata
Title
The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group
Authors
Prakash Chinnaiyan
Meihua Wang
Amyn M Rojiani
Philip J Tofilon
Arnab Chakravarti
K Kian Ang
Hua-Zhong Zhang
Elizabeth Hammond
Walter Curran Jr
Minesh P Mehta
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2008
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-3-32

Other articles of this Issue 1/2008

Radiation Oncology 1/2008 Go to the issue

Research

A psychoeducational intervention reduces the need for anesthesia during radiotherapy for young childhood cancer patients

Research

Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study

Research

Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking

Research

Intrafraction motion of the prostate during an IMRT session: a fiducial-based 3D measurement with Cone-beam CT

Research

Investigation of the usability of conebeam CT data sets for dose calculation

Research

Dose volume histogram analysis of normal structures associated with accelerated partial breast irradiation delivered by high dose rate brachytherapy and comparison with whole breast external beam radiotherapy fields